FindTrial
Sign In

Temozolomide Accord 20 mg hard capsules.

DRUG3 trials

Sponsors

Helse Bergen HF, Medical University Of Vienna, Universitair Medisch Centrum Utrecht

Conditions

Diffuse Midline GliomaGrade IV recurrent glioma which includes both glioblastomaH3K27-alteredclassified as IDH wt and grade IV IDH mutated astrocytoma.ependymoma and atypical teratoid rhabdoid tumor (ATRT)rare CNS tumorsrecurrent/progressive medulloblastoma

Phase 1

BORTEZOMIB SENSITIZATION OF RECURRENT GRADE-4 GLIOMA WITH UNMETHYLATED MGMT PROMOTER TO TEMOZOLOMIDE. PHASE IB/II. (BORTEM 17)
RecruitingCTIS2024-515142-16-00
Helse Bergen HFclassified as IDH wt and grade IV IDH mutated astrocytoma., Grade IV recurrent glioma which includes both glioblastoma
Start: 2024-10-03Target: 63Updated: 2024-10-02
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial
Not yet recruitingCTIS2025-520814-78-00
Universitair Medisch Centrum UtrechtDiffuse Midline Glioma, H3K27-altered
Target: 20Updated: 2026-03-23

Phase 2

MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors
RecruitingCTIS2024-515626-92-00
Medical University Of Viennaependymoma and atypical teratoid rhabdoid tumor (ATRT), rare CNS tumors, recurrent/progressive medulloblastoma
Start: 2013-10-18Target: 100Updated: 2025-11-28